<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1735">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05138575</url>
  </required_header>
  <id_info>
    <org_study_id>849401</org_study_id>
    <nct_id>NCT05138575</nct_id>
  </id_info>
  <brief_title>SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial</brief_title>
  <official_title>SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test whether pharmacologic agents that may improve mitochondrial function and&#xD;
      energy fuel metabolism [Empagliflozin (Empa)], with and without additional supplements that&#xD;
      increase perfusion and fatty acid oxidation [Potassium Nitrate (KNO3)], improve submaximal&#xD;
      exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in&#xD;
      participants with Heart Failure with Preserved Ejection Fraction (HFpEF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test whether Empagliflozin (Empa), with and without Potassium Nitrate (KNO3),&#xD;
      improves submaximal exercise endurance, skeletal muscle oxidative phosphorylation capacity&#xD;
      (SkM OxPhos), intramuscular perfusion, and changes in the skeletal muscle metabolome,&#xD;
      proteome, and respiration in participants with Heart Failure with Preserved Ejection Fraction&#xD;
      (HFpEF).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>3 interventions will be randomized and administered in a double-blind fashion</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All personnel will be masked except for the IDS pharmacist dispensing the drugs.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Submaximal Exercise Endurance</measure>
    <time_frame>Week 6</time_frame>
    <description>Time to exhaustion while exercising at 75% peak workload</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intramuscular Perfusion</measure>
    <time_frame>Week 6</time_frame>
    <description>MRI assessment of skeletal muscle perfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VO2 Kinetics</measure>
    <time_frame>Week 6</time_frame>
    <description>Assess the impact of interventions on the kinetics of oxygen consumption (VO2 kinetics) during exercise and recovery. &quot;On&quot; and &quot;Off&quot; kinetics will be modeled during the submaximal exercise transient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VO2 Efficiency</measure>
    <time_frame>Week 6</time_frame>
    <description>Assess the impact of interventions on the efficiency of oxygen consumed above basal metabolic rate compared to total work performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasodilatory Reserve</measure>
    <time_frame>Week 6</time_frame>
    <description>Percent change in systemic vascular resistance (SVR) at baseline vs SVR at 4 minutes of exercise at end of each intervention period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Substrate Concentration</measure>
    <time_frame>Week 6</time_frame>
    <description>Change in venous substrate concentrations at 4 minutes of exercise at end of each intervention period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Exchange Ratio</measure>
    <time_frame>Week 6</time_frame>
    <description>Change in RER at 4 minutes of exercise at end of each intervention period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KCCQ Overall Summary Score</measure>
    <time_frame>Week 6</time_frame>
    <description>Assess impact of interventions on quality of life based on Kansas City Cardiomyopathy Questionnaire overall summary score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory Physical Activity</measure>
    <time_frame>Week 6</time_frame>
    <description>Use actigraphy to document the average steps per day taken during the final week of each interventional period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Tissue Respirometry</measure>
    <time_frame>Week 6</time_frame>
    <description>Measure tissue rates of substrate metabolism and mitochondrial content</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Proteome</measure>
    <time_frame>Week 6</time_frame>
    <description>Measure relative abundances of proteins related to fatty acid and ketone oxidation as well as proteins related to mitochondrial biogenesis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Metabolome</measure>
    <time_frame>Week 6</time_frame>
    <description>Perform targeted quantitative metabolomics to assess changes in substrate metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal Muscle Oxidative Capacity</measure>
    <time_frame>Week 6</time_frame>
    <description>MRI assessment of skeletal muscle oxidative phosphorylation capacity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intramyocardial Filling Pressure</measure>
    <time_frame>Week 6</time_frame>
    <description>Assess impact of interventions on intramyocardial filling pressures during submaximal exercise</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Empagliflozin + Potassium Chloride (KCl)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Empagliflozin (10 mg daily) + Potassium Chloride (6 mmol three times daily)&#xD;
Active arm will be 6 weeks in duration followed by a 2 week washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin + Potassium Nitrate (KNO3)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Empagliflozin (10 mg daily) + Potassium Nitrate (6 mmol three times daily)&#xD;
Active arm will be 6 weeks in duration followed by a 2 week washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Potassium Chloride (KCl) + Placebo for Empa</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Potassium Chloride (6 mmol three times daily) + Placebo for Empagliflozin&#xD;
Placebo arm will be 6 weeks in duration followed by a 2 week washout period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin + Potassium Chloride</intervention_name>
    <description>Empagliflozin is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle.&#xD;
KCl is an active control.</description>
    <arm_group_label>Empagliflozin + Potassium Chloride (KCl)</arm_group_label>
    <other_name>Jardiance + KCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin + Potassium Nitrate</intervention_name>
    <description>Empagliflozin + KNO3 is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle, as well as increase skeletal muscle perfusion during exercise.</description>
    <arm_group_label>Empagliflozin + Potassium Nitrate (KNO3)</arm_group_label>
    <other_name>Jardiance + KNO3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium Chloride + Placebo for Empagliflozin</intervention_name>
    <description>Active control.</description>
    <arm_group_label>Potassium Chloride (KCl) + Placebo for Empa</arm_group_label>
    <other_name>KCl + Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. NYHA Class II-III symptoms&#xD;
&#xD;
          2. Left ventricular ejection fraction &gt;= 50%&#xD;
&#xD;
          3. Stable medical therapy for at least 1 month, defined as: no addition/removal/changes&#xD;
             in antihypertensive medications or beta-blockers in the preceding 30 days and&#xD;
             continuation of a stable diuretic regimen, if applicable&#xD;
&#xD;
          4. Prior or current evidence for elevated filling pressures as follows:&#xD;
&#xD;
               1. Mitral early (E)/septal tissue annular (e') velocity ratio &gt; 8, in the context of&#xD;
                  a septal e' velocity &lt;=7 cm/s or a lateral e' &lt;= 10 cm/s, in addition to one of&#xD;
                  the following: i. Large left atrium (LA volume index &gt; 34 mL/m2), ii. Chronic&#xD;
                  loop diuretic use for control of symptoms, iii. Elevated natriuretic peptides&#xD;
                  within the past year (e.g. NTproBNP &gt; 125 pg/mL in sinus rhythm or &gt; 375 pg/mL if&#xD;
                  in atrial fibrillation)&#xD;
&#xD;
               2. Mitral E/e' ratio &gt; 14 at rest or during exercise&#xD;
&#xD;
               3. Elevated invasively-determined filling pressures previously (resting left&#xD;
                  ventricular end-diastolic pressure &gt;= 16 mm Hg or pulmonary capillary wedge&#xD;
                  pressure &gt;= 15 mmHg; or PCWP/LVEDP &gt;= 25 mmHg with exercise)&#xD;
&#xD;
               4. Prior episode of acute heart failure requiring IV diuretics&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt;18 years old&#xD;
&#xD;
          2. Pregnancy: Women of childbearing potential will undergo a urine pregnancy test during&#xD;
             the screening visit. We note that the advanced age of HFpEF subjects (median age of 78&#xD;
             in the Get With the Guidelines-HF program) will make it unlikely that pre-menopausal&#xD;
             females will be enrolled.&#xD;
&#xD;
          3. Treatment with organic nitrates or phosphodiesterase inhibitors that cannot be&#xD;
             interrupted&#xD;
&#xD;
          4. Uncontrolled atrial fibrillation, as defined by a resting heart rate &gt; 100 beats per&#xD;
             minute at the time of the baseline assessment&#xD;
&#xD;
          5. Hemoglobin &lt; 10 g/dL&#xD;
&#xD;
          6. Subject inability/unwillingness to exercise&#xD;
&#xD;
          7. Moderate or greater left sided valvular disease (mitral regurgitation, aortic&#xD;
             stenosis, aortic regurgitation), mild or greater mitral stenosis, severe right-sided&#xD;
             valvular disease&#xD;
&#xD;
          8. Known hypertrophic, infiltrative, or inflammatory cardiomyopathy&#xD;
&#xD;
          9. Clinically significant pericardial disease, as per investigator judgment&#xD;
&#xD;
         10. Current angina due to clinically significant epicardial coronary disease, as per&#xD;
             investigator judgment&#xD;
&#xD;
         11. Acute coronary syndrome or coronary intervention within the past 2 months&#xD;
&#xD;
         12. Primary pulmonary artery hypertension (WHO Group 1 Pulmonary Arterial Hypertension)&#xD;
&#xD;
         13. Clinically significant lung disease as defined by: Chronic Obstructive Pulmonary&#xD;
             Disease Stage III or greater GOLD criteria (FEV1&lt;50%), treatment with oral steroids&#xD;
             within the past 6 months for an exacerbation of obstructive lung disease, current use&#xD;
             of supplemental oxygen aside from nocturnal oxygen for the treatment of obstructive&#xD;
             sleep apnea.&#xD;
&#xD;
               -  Desaturation to &lt;90% on the baseline maximal effort cardiopulmonary exercise test&#xD;
                  will also be grounds for exclusion&#xD;
&#xD;
         14. Clinically-significant ischemia, as per investigator's judgement, on stress testing&#xD;
             without either (1) subsequent revascularization, (2) an angiogram demonstrating the&#xD;
             absence of clinically significant epicardial coronary artery disease, as per&#xD;
             investigator judgment; (3) a follow-up 'negative' stress test, particularly when using&#xD;
             a more specific technique (i.e., a negative perfusion imaging test following a&#xD;
             'positive' ECG stress test)&#xD;
&#xD;
               -  Exercise-induced regional wall motion abnormalities on the echocardiographic&#xD;
                  assessment during the baseline maximal effort cardiopulmonary exercise test will&#xD;
                  also be exclusionary&#xD;
&#xD;
         15. Left ventricular ejection fraction &lt; 45% on a prior echocardiogram or cardiac MRI&#xD;
&#xD;
         16. Significant liver disease impacting synthetic function or volume control (ALT/AST &gt; 3x&#xD;
             ULN, Albumin &lt; 3.0 g/dL)&#xD;
&#xD;
         17. eGFR &lt; 45 mL/min/1.73m^2. We note that while the FDA packing insert suggests a lower&#xD;
             limit of 45 mL/min/1.73 m2 for Empa, the EMPERIOR Reduced trial enrolled HFrEF&#xD;
             participants with an eGFR &gt;= 20 mL/min/1.73m2.(59)&#xD;
&#xD;
         18. Methemoglobin &gt; 5%&#xD;
&#xD;
         19. Serum potassium &gt; 5.0 mEq/L on baseline testing&#xD;
&#xD;
         20. Type I Diabetes&#xD;
&#xD;
         21. History of ketoacidosis&#xD;
&#xD;
         22. Current use of or prior intolerance to an SGLT2i&#xD;
&#xD;
         23. Ongoing maintenance of a 'Ketogenic Diet' (low carbohydrate, high fat)&#xD;
&#xD;
         24. Allergy to beets&#xD;
&#xD;
         25. Severe right ventricular dysfunction&#xD;
&#xD;
         26. Baseline resting seated systolic blood pressure &gt; 180 mmHg or &lt; 100 mmHg&#xD;
&#xD;
         27. Orthostatic blood pressure response to the transition from supine to standing (&gt;20&#xD;
             mmHg reduction in systolic blood pressure 2-3 minutes after standing, or a fall in SBP&#xD;
             to &lt; 90 mmHg)&#xD;
&#xD;
         28. Active participation in another study that utilizes an investigational agent&#xD;
             (observational studies/registries allowed)&#xD;
&#xD;
         29. Any condition that, in the opinion of the investigator, will interfere with the&#xD;
             completion of the study. This may include comorbid or psychiatric conditions that may&#xD;
             impede successful completion of the protocol, or logistical concerns (e.g. inability&#xD;
             to travel to the exercise unit).&#xD;
&#xD;
         30. Contraindications to MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Payman Zamani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole Tafuna'i</last_name>
    <phone>(801) 831-1044</phone>
    <email>Nicole.Tafunai@Pennmedicine.upenn.edu</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Payman Zamani, MD</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be maintained indefinitely in an electronic database. This will not include the participant's contact or identifying information. Rather, individual participants and their research data will be identified by a unique study identification number. The study data entry and study management systems used by clinical sites and by the research staff will be secured and password protected. At the end of the study, all study databases will be de-identified and archived.&#xD;
If any data or samples are shared with collaborators at UPenn or elsewhere, only de-identified samples/data will be given, without any linking information.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 28, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT05138575/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 28, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT05138575/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

